DelveInsight launched a new report on “Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Insights, Epidemiology, and Market Forecast 2030.”
Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) is a different kind of inflammatory arthritis. It falls under an umbrella category of diseases called spondyloarthritis, which includes different types of arthritis with one distinguishing feature. There is almost always inflammation in the spine.
Back pain is “the hallmark of Non-Radiographic Axial Spondyloarthritis, which sets it apart from any other type of inflammatory arthritis. “Non-radiographic” means the disease causes symptoms, but there is no visible damage on X-rays, the way there is with a related type of inflammatory arthritis called ankylosing spondylitis.
DelveInsight’s “Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Report 2030“ delivers an in-depth understanding of the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA), historical and forecasted epidemiology as well as the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Request for sample pages of the report: https://www.delveinsight.com/sample-request/non-radiographic-axial-spondyloarthritis-nr-axspa-market
Non-Radiographic Axial Spondyloarthritis Symptoms:
- Pain and stiffness in the back or buttocks.
- Pain that worsens after rest (for example, after waking up) and is relieved by exercise.
- Pain in tendons (which connect muscles to bones) and ligaments (which connect bones), often felt as pain at the front of the chest, back of the heel or underneath the foot.
“The prevalence of human leukocyte antigen B27 (HLA-B27) was similar for nr-axSpA and AS which is 86.4% for nr-axSpA vs. 89.1% for AS, 74.7% for nr-axSpA vs. 82.2% for AS, and 74.8% for nr-axSpA vs. 81.5% AS.”
Non-Radiographic Axial Spondyloarthritis Key pharma players involved:
- Novartis Pharmaceuticals
- UCB Biopharma
- Galapagos NV
- And others.
Table of contents:
1 Key Insight
2 Executive Summary of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA)
3 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Overview at a Glance
4 Disease Background and Overview: Non-Radiographic Axial Spondyloarthritis (nr-AxSpA)
5 Case Reports
6 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Treatment and Medical Practices
11 Unmet needs
12 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Marketed Drugs
13 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Emerging Drugs
14 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Drivers
19 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight
Download full report: https://www.delveinsight.com/sample-request/non-radiographic-axial-spondyloarthritis-nr-axspa-market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/
